Your session is about to expire
← Back to Search
Nivolumab + Radiation for Gastroesophageal Cancer
Study Summary
This trial is testing if nivolumab alone or with radiation therapy can help people with cancer who didn't respond to initial treatment with FOLFOX and nivolumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.My cancer is HER2 positive adenocarcinoma.I was treated for cancer other than prostate or skin cancer less than 3 years ago.I am older than 18 years.I have advanced cancer that started in my stomach or esophagus and it can't be removed by surgery.I have another cancer, but it's either skin cancer treated with the intent to cure, or in situ cervical cancer.I agree to provide a recent biopsy sample of my tumor.I am currently on medication for an infection.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.I have not received a live vaccine in the last 30 days.I agree to use birth control and, if I'm a woman who can have children, I have a recent negative pregnancy test.I've had chemotherapy for cancer that couldn't be cured, but it's been over 6 months since my last treatment.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I have an active tuberculosis infection.I have or had lung inflammation not caused by an infection.My kidney function is normal or near normal.I am fully active and can carry on all pre-disease activities without restriction.
- Group 1: Cohort 1
- Group 2: Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities in the US are currently executing this experiment?
"Patients are being recruited from five different medical centres, spread among Omaha, New york and Tampa as well as two other cities. It is recommended that you select the closest site to reduce travel needs in case of enrolment."
Does this research represent a pioneering effort in its field?
"Nivolumab 240 MG has been subject to research since 2012, with Ono Pharmaceutical Co. Ltd. leading the inaugural trial involving 659 participants. After completing Phase 1 & 2 trials successfully, this drug is now being actively studied in 718 studies across 2354 cities and 49 nations worldwide."
Are there any vacancies available in this medical experiment?
"Affirmative. Clinicaltrials.gov states that the trial, initiated on July 22nd 2019, is actively seeking participants and has recently been updated as of June 29th 2022. 74 volunteers are sought from 5 distinct clinical sites."
Has there been any prior research into the efficacy of Nivolumab 240 MG?
"Nivolumab 240 MG was initially trialed in 2012 at a Local Institution, currently there are 250 completed trials and 718 ongoing studies. Notably, many of the recruiting sites for these clinical trials can be found in Omaha, Nebraska."
What diseases are typically addressed with an injection of Nivolumab 240 MG?
"Nivolumab 240 MG is commonly used to battle malignant neoplasms and can also be applied in the treatment of conditions like metastatic esophageal adenocarcinoma, squamous cell carcinoma, or unresectable melanoma."
Has the US Food and Drug Administration sanctioned Nivolumab 240 MG?
"The safety of Nivolumab 240 MG was assigned a score of 2, as Phase 2 trials have only provided evidence to support its security rather than efficacy."
Share this study with friends
Copy Link
Messenger